- Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
- Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
- Kymera Therapeutics to Participate in Upcoming March Investor Conferences
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
- Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
- Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
- Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Kymera Therapeutics Announces Pricing of $275 Million Public Offering
More ▼
Key statistics
As of last trade Kymera Therapeutics Inc (KYMR:NMQ) traded at 33.59, -25.86% below its 52-week high of 45.31, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.28 |
---|---|
High | 34.28 |
Low | 32.75 |
Bid | 33.46 |
Offer | 33.58 |
Previous close | 35.21 |
Average volume | 503.77k |
---|---|
Shares outstanding | 61.11m |
Free float | 60.27m |
P/E (TTM) | -- |
Market cap | 2.15bn USD |
EPS (TTM) | -2.52 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 17:53 BST.
More ▼